High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes

Blood

Volumn 98, Issue 13, 2001, Pages 3800-3808

  Zweigner, Janine ^a,b   Gramm, Hans Joachim ^a,b   Singer, Oliver C ^a,b   Wegscheider, Karl ^a,b   Schumann, Ralf R ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CD14 ANTIGEN; CYTOKINE; FLUORESCEIN ISOTHIOCYANATE; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CATALYSIS; CELL SORTER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DEFENSE MECHANISM; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FLUORESCENCE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PERITONITIS; PRIORITY JOURNAL; PROTEIN BINDING; SEPSIS; SEPTIC SHOCK;

EID: 0035895085     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.13.3800     Document Type: Article

References (56)

1. Ulevitch RJ, Tobias PS. Recognition of gramnegative bacteria and endotoxin by the innate immune system. Curr Opin Immunol. 1999;11:19-22.
2. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
3. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-874.
4. Abraham E, Matthay MA, Dinarello CA, et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit Care Med. 2000;28:232-235.
5. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med. 2000;26:S64-S74.
6. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units. JAMA. 1995;274:968-974.
7. Natanson C, Esposito CJ, Banks SM, Magnuson WG. The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med. 1998;26:1927-1931.
8. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med. 1999;340:207-214.
9. Nathan CF. Secretory products of macrophages. J Clin Invest. 1987;79:319-326.
10. Medzhitov R, Janeway C. Innate immunity. N Engl J Med. 2000;343:338-344.
11. Rietschel ET, Brade H, Hoist O, et al. Bacterial endotoxin: chemical constitution, biological recognition, host response, and immunological detoxification. Curr Top Microbiol Immunol. 1996;216:39-81.
12. Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science. 1990;249:1429-1431.
13. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431-1433.
14. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085-2088.
15. Schumann RR, Kirschning CJ, Unbehaun A, et al. The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT-3 and other cytokine-inducible nuclear proteins. Mol Cell Biol. 1996;16:3490-3503.
16. Opal SM, Scannon PJ, Vincent J-L, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999;180:1584-1589.
17. Froon AHM, Dentener MA, Greve JWM, Ramsay G, Buurman WA. Lipopolysaccharide toxicity-regulating proteins in bacteremia. J Infect Dis. 1995;171:1250-1257.
18. Gallay P, Barras C, Tobias PS, Calandra T, Glauser MP, Heumann D. Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS. J Infect Dis. 1994;170:1319-1322.
19. Vreugdenhil ACE, Dentener MA, Snoek AMP, Greve JWM, Buurman WA. Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J Immunol. 1999;163:2792-2798.
20. Dentener MA, Vreugdenhil ACE, Hoet PH, et al. Production of the acute-phase protein lipopolysaccharide-binding protein by respiratory type II epithelial cells: implications for local defense to bacterial endotoxins. Am J Respir Cell Mol Biol. 2000;23:146-153.
21. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994;180:1025-1035.
22. Hailman E, Albers JJ, Wolfbauer G, Tu A-Y, Wright SD. Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J Biol Chem. 1996;271:12172-12178.
23. Jack RS, Fan X, Bernheiden M, et al. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature. 1997;389:742-745.
24. Lamping N, Dettmer R, Schröder NWI, et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest. 1998;101:2065-2071.
25. Balakrishnan VS, Schmid CH, Jaber BL, Natov SN, King AJ, Pereira BJG. Interleukin-1 receptor antagonist synthesis by peripheral blood mononuclear cells: a novel predictor of morbidity among hemodialysis patients. J Am Soc Nephrol. 2000;11:2114-2121.
26. Ertel W, Kremer J-P, Kenney J, et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood. 1995;85:1341-1347.
27. Marie C, Muret J, Fitting C, Losser M-R, Payen D, Cavaillon J-M. Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory syndrome. Blood. 1998;91:3439-3446.
28. Munoz C, Carlet J, Fitting C, Misset B, Blériot J-P, Cavaillon J-M. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991;88:1747-1754.
29. Wolk K, Döcke W-D, von Baehr V, Volk H-D, Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood. 2000;96:218-223.
30. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991;100:1619-1636.
31. Vincent J-L, Moreno R, Takala J, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707-710.
32. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128-140.
33. Berger D, Schleich S, Seidelmann M, Beger HG. Correlation between endotoxin-neutralizing capacity of human plasma as tested by the limulus amebocyte-lysate-test and plasma protein levels. FEBS Lett. 1990;277:33-36.
34. Döcke W-D, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med. 1997;3:678-681.
35. Gallay P, Heumann D, Le Roy D, Barras C, Glauser M-P. Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc Natl Acad Sci U S A. 1994;91:7922-7926.
36. Le Roy D, Di Padova F, Tees R, et al. Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14. J Immunol. 1999;162:7454-7460.
37. Wurfel MM, Monks BG, Ingalls RR, et al. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med. 1997;186:2051-2056.
38. Wurfel MM, Wright SD. Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers: preferential interaction with particular classes of lipid. J Immunol. 1997;158:3925-3934.
39. Vreugdenhil ACE, Snoek AMP, van't Veer C, Greve JWM, Buurman WA. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest. 2001;107:225-234.
40. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1993;90:12040-12044.
41. Gegner JA, Ulevitch RJ, Tobias PS. Lipopolysaccharide (LPS) signal transduction and clearance: dual roles for LPS binding protein and membrane CD14. J Biol Chem. 1995;270:5320-5325.
42. Hamann L, Schumann RR, Flad HD, Brade L, Rietschel ET, Ulmer AJ. Binding of lipopolysaccharide (LPS) to CHO cells does not correlate with LPS-induced NF-κB activation. Eur J Immunol. 2000;30:211-216.
43. Moore KJ, Andersson LP, Ingalls RR, et al. Divergent response to LPS and bacteria in CD14-deficient murine macrophages. J Immunol. 2000;165:4272-4280.
44. Haziot A, Hijiya N, Gangloff SC, Silver J, Goyert SM. Induction of a novel mechanism of accelarated bacterial clearance by lipopolysaccharide in CD14-deficient and Toll-like receptor 4-deficient mice. J Immunol. 2001;166:1075-1078.
45. Triantafilu K, Triantafilu M, Dedrick RL. A CD14-independent LPS receptor cluster. Nat Immunol. 2001;2:338-345.
46. Frey EA, Miller DS, Jahr TG, et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med. 1992;176:1665-1671.
47. Pugin J, Schürer-Maly C-C, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci U S A. 1993;90:2744-2748.
48. Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high-density lipoprotein. J Exp Med. 1995;181:1743-1754.
49. Haziot A, Rong G-W, Bazil V, Silver J, Goyert SM. Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-α production by cells in whole blood. J Immunol. 1994;152:5868-5876.
50. Calvano SE, Thompson WA, Marra MN, et al. Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. Arch Surg. 1994;129:220-226.
51. Dentener MA, von Asmuth EJU, Francot GJM, Marra MN, Buurman WA. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes: competition for binding to lipopolysaccharide. J Immunol. 1993;151:4258-4265.
52. de Haas CJC, Poppelier MJJG, Van Kessel KPM, Van Strijp JAG. Serum amyloid P component prevents high-density lipoprotein-mediated neutralization of lipopolysaccharide. Infect Immun. 2000;68:4954-4960.
53. Heumann D, Gallay P, Betz-Corradin S, Barras C, Baumgartner J-D, Glauser MP. Competition between bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes. J Infect Dis. 1993;167:1351-1357.
54. Heumann D, Adachi Y, Le Roy D, et al. Role of plasma, lipopolysaccharide-binding protein, and CD14 in response of mouse peritoneal exudate macrophages to endotoxin. Infect Immun. 2001;69:378-385.
55. Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med. 1996;184:1601-1608.
56. Gordon BR, Parker TS, Levine DM, et al. Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med. 1996;24:584-589.